A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. (Q44138021)
Jump to navigation
Jump to search
scientific article published in September 2002
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. |
scientific article published in September 2002 |
Statements
1 reference
A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. (English)
1 reference
P Iversen
1 reference
T L J Tammela
1 reference
S Vaage
1 reference
O Lukkarinen
1 reference
P Lodding
1 reference
T Bull-Njaa
1 reference
J Viitanen
1 reference
P Hoisaeter
1 reference
P Lundmo
1 reference
F Rasmussen
1 reference
J-E Johansson
1 reference
B-E Persson
1 reference
K Carroll
1 reference
Scandinavian Prostatic Cancer Group (SPCG)
1 reference
1 September 2002
1 reference
1 reference
42
1 reference
3
1 reference
204-211
1 reference
Identifiers
1 reference
1 reference